# Heron Corporate Update

November 18, 2021




### **Forward-Looking Statements**

This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, those associated with: the timing of the commercial launch of ZYNRELEF in Europe; the potential market opportunity for ZYNRELEF in the US and Europe; the timing of the FDA's review process and whether the FDA approves the supplemental NDA for ZYNRELEF to expand the U.S. label to related procedures; the potential additional market opportunity for the expanded U.S. label; the timing and results of studies for the further expansion of the U.S. label for ZYNRELEF; the timing and results of studies for the HTX-034 development program; the timing of the FDA's review process and whether the FDA approves the NDA for HTX-019 for prevention of postoperative nausea and vomiting; the net product sales guidance for the oncology care franchise; the expected future balances of Heron's cash, cash equivalents and short-term investments; the expected duration over which Heron's cash, cash equivalents and short-term investments balances will fund its operations; the extent of the impact of the ongoing Coronavirus Disease 2019 (COVID-19) pandemic on our business; and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and we take no obligation to update or revise these statements except as may be required by law.



### **Heron Pipeline**



HTX-034 and HTX-019 (for PONV) are investigational new drugs and are not approved by the FDA

3

## HTX-019 for Postoperative Nausea and Vomiting (PONV)

## **NDA Submitted November 2021**



HTX-019 is an investigational new drug for PONV and not approved by the FDA

4

# **HTX-019 for PONV**

5

- PONV is a large market ~20x the size of CINV
- HTX-019 has significant potential advantages over oral aprepitant and IV fosaprepitant:
  - Therapeutic plasma concentrations where ≥97% receptor occupancy in the brain would be predicted are achieved in minutes versus >1 hour for oral aprepitant
  - 30-second administration of HTX-019 versus 20-30 minutes for fosaprepitant
  - IV fosaprepitant can be very painful when administered into a peripheral vein (In prior BE comparison HTX-019 was better tolerated than EMEND IV, with 65% fewer AEs at least possibly related to treatment and no AEs of greater than mild severity)
- NDA for prevention of PONV in adults submitted November 2021
- Several hundred million dollar a year potential market opportunity, taking the majority of the oral aprepitant market and use in high risk procedures

HTX-019 is an investigational new drug for PONV and not approved by the FDA

## Aprepitant Efficacy – Large Differential in Vomiting Episodes Compared to Ondansetron\*




Figure 5. Kaplan-Meier curves for the time to first vomiting during the 48 h following surgery. The time to first vomiting was delayed by aprepitant; *P* 0.001 based on the log-rank test.


Aprepitant delayed the time to first vomiting episode compared with ondansetron.

\*Published results from Gan TJ, et al. Ambul Anesth. 2007; 1082-89.


HTX-019 is an investigational new drug for PONV and not approved by the FDA

\_

### PONV Market is >20X the size of the CINV Market PONV ~53M Treatments vs. ~2.5M CINV Treatments



- Approximately 65M diagnostic and surgical procedures are at risk of resulting in PONV in the US
- More than half of these patients are at moderate to high risk of PONV




THERAPEUTICS

Source: PONV quantitative survey DRG June 2020

HTX-019 is an investigational new drug for PONV and not approved by the FDA

### 100% Receptor Occupancy Occurs Much Faster With HTX-019 30-Second Administration Than with Oral Aprepitant




HTX-019 is an investigational new drug for PONV and not approved by the FDA

8

### **Oral Aprepitant is Already Rapidly Growing** with No Promotion, Product Limitations and High Acquisition Cost

•



<sup>2021-2023</sup> Projected Totals: 2021 YTD thru 10 months 32% growth vs. prior year / 2022 & 2023 projected at 25% growth

- Oral Aprepitant volume is growing rapidly at premium price despite no promotion
  - Q2'21 WAC ~ \$88/capsule
- ~ 1,100 current ordering accounts<sup>1</sup>

#### • HTX-019 advantages vs. Oral Aprepitant

- Flexible 30-second IVP vs. oral administration
- Onset of action 5 minutes vs. 1 to 3 hours
- Heron product promotion efforts

#### Strategic fit with HTX-011

- Same commercial organization
- Same Hospital & ASC targets
- Same surgeon, anesthesiology & pharmacy targets
- New class (NK1) is needed based on existing PONV guidelines



<sup>1</sup> Source IQVIA DDD Non-Retail data 2017 -2021

HTX-019 is an investigational new drug for PONV and not approved by the FDA

9

## HTX-019 for PONV is Ideal Strategic Fit for Heron

- Large market ~ 14M target surgical procedures with significant unmet need for more convenient formulations of NK-1 class drugs
- Potential Significant Advantages of HTX-019
  - 30-second IV Push injection with immediate onset of action and no difference in AEs versus oral formulation
  - Aprepitant is the most effective therapeutic agent for emesis
  - 505(b)(2) regulatory pathway for existing asset
  - Existing contract manufacturers
- Synergies with ZYNRELEF commercial organization
  - Same target accounts and target audiences
  - Capacity & access advantages of adding a 2nd product to promote
  - Minimal incremental investment will improve ROI

HTX-019 is an investigational new drug for PONV and not approved by the FDA



# ZYNRELEF<sup>™</sup> (bupivacaine and meloxicam) Extended-Release Solution



### Why Approval of ZYNRELEF is so Important Postoperative Opioids Can Be a Doorway to Addiction

#### More than 50 million

surgical procedures happen in the United States.<sup>1</sup>

#### 67% of patients

filled an opioid prescription between 30 days before through 14 days after surgery.<sup>2\*</sup>

#### > 2 million Americans


may become persistent opioid users annually after surgery.<sup>1</sup>

In 2020, drug overdoses were linked to more than

#### 90,000 deaths

the highest number ever recorded in a single year.<sup>3</sup>

In addition, most patients take fewer opioids than the amount prescribed after surgery, resulting in excess opioid pills that are accessible to others.<sup>4</sup>



More than \$23.4 billion

in annual healthcare costs associated with persistent opioid users can be attributed to postoperative pain management.<sup>1,6</sup>

THERAPEUTICS

\* This was determined using a 20% national sample of Medicare claims among beneficiaries aged 65 and older with Medicare Part D claims who underwent a major or minor surgical procedure between January 1, 2009 and June 30, 2015.

References: 1. Brummett CM, Waljee JF, Gossling J, et al. New Persistent Opicid Use After Minor and Najo Surgical Procedures in US Adults [published correction appears in JAMA Surg. 2019 Mar 1;154(3):272]. JAMA Surg. 2017;152(1):478-64. doi:10.1001/jamasurg2017.050(4). 2. Santoas KB, Hu HM, Brummett CM, et al. New persistent opicid use among older patients following surgery P. Medicare of taims analysis. Surgery. 2020;167(1):732-742. doi:10.1016/j.surg.2019.04.016.3. NCHS, National Vital Statistics System: Estimates for 2015 are based on provisional data. Estimates for 2015 2019 are based on fraid data (available from: <u>https://www.dc.gov/nchs/nyssimotality.public.use.data.htm)</u>. 4. Bicket MC, Long JJ, Pronovest PJ, Nearander SC, Wu CL. Prescription Opicid Analgesics Commonly Unused After Surgery: A Systemate Review. JAMA Surg. 2017;152(1):1066-1071. doi:10.101/jamasurg.2017.0831.f. Substance Abuse and Mental Health Services Administration. Conter for Behaviora Health Statistics and Ouality. Substance Abuse and Mental Health Services Administration. Ecolville, MD: 2019. eVery Substance Abuse and Mental Health Services Administration. Rockville, MD: 2019. eVery Substance Abuse and Mental Health Services Administration. Rockville, MD: 2019. eVery Substance Abuse and Mental Health Services Administration. Rockville, MD: 2019. eVery Substance Abuse and Mental Health Services Administration. Rockville, MD: 2019. eVery Substance Abuse and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (Health (HHS Publication No. EVP19-5068. NSDUH Series H-53. https://www.astatisted/atu/Hite/Substanle/BridgeRept2018.18.2011. Accessed April 19.2021. 6. Burnmett CM, Evans-Shields J, England C, Kong AM, Lew CR, Henriques C, Zimmerman NM, Sun EC. Increased health care costs associated with new persistent opicid use after major surgery in opicid-naive patients. *J Manag Care Spec Pharm.* 2021 Feb 24:1-12. doi: 10.1853/jmrcp.2021.20507. EUPID: 33824354.


### **ZYNRELEF Approved Indications and Limitations of Use**

#### Indication

 ZYNRELEF is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

#### Limitations of Use

• Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.



### **ZYNRELEF** is First of a New Class of Local Anesthetic

- ZYNRELEF is first and only local anesthetic to be classified by FDA as "extendedrelease" based on superiority to bupivacaine HCl for 72 hours
- FDA recognized ZYRELEF's unique Mechanism of Action (MOA)
  - Compared with bupivacaine alone in both studies, ZYNRELEF (at the same bupivacaine doses) demonstrated greater and longer analgesia through 24, 48, and 72 hours
  - The only dual-acting extended-release local anesthetic
- ZYNRELEF is only local anesthetic demonstrating superiority to bupivacaine (standard of care):
  - Statistically superior pain reduction compared to bupivacaine and placebo arms where patients took significantly more opioids
  - Statistically superior opioid-free results
- ZYNRELEF has superior reduction in pain for total knee arthroplasty (TKA), most painful surgery, included in label

## Successful FDA Interactions to Support Expansion of ZYNRELEF Label and Increase Product Supply

- FDA agreed to submission of supplemental NDA with existing data to significantly expand ZYNRELEF indications to include foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
  - Supplemental NDA submitted in late September
- FDA also agreed to contents of a second supplemental NDA to substantially further expand the indications to orthopedic surgical procedures and soft tissue surgical procedures.
  - Submission targeted for 2H2022
  - Expanded broad claim structure designed to cover 14 million target procedures
- FDA approved manufacturing supplement to NDA to add secondary supplier of our proprietary polymer.
  - Approval received in under 4 months
  - Allows for polymer batch size of sufficient to manufacture millions of doses of ZYNRELEF annually at a significantly reduced cost of goods



The first and only extended-release, dual-acting local anesthetic (DALA), keeping more patients out of severe pain and opioid-free for 72 hours after surgery<sup>1-3</sup>

References: 1. ZYNRELEF [package insert]. San Diego, CA: Heron Therapeutics Inc; 2021. 2. Viscusi E, Gimbel JS, Pollack RA, et al. *Reg Anesth Pain Med*. 2019;44(7):700-706. 3. Viscusi E, Minkowitz H, Winkle P, et al. *Hernia*. 2019;23(6):1071-1080.



Please see IMPORTANT SAFETY INFORMATION on pages 28 to 29 and full Prescribing Information, including Boxed Warning.


16

## **ZYNRELEF** Launch is Off to a Strong Start

- Q3'21 Net Sales: \$2.1M
- ZYNRELEF has established nationwide access through broad distribution channel stocking
  - 4 Full-line Wholesaler with 68 distribution centers (DCs) have sold ZYNRELEF
    - 50% of DCs have reordered
  - 10 Specialty Distributor (DCs) have sold ZYNRELEF
    - 60% of DCs have reordered



### **Comparison of Select Hospital Launches**



Product	Launch Date	Q1	Q2	Q3	Q4	Q5	Q6	Q1-Q6 TOTAL
Ofirmev	Jan 2011	\$0.4	\$1.7	\$3.5	\$5.9	\$8.0	\$11.1	\$30.6
Exparel	April 2012	\$2.3	\$4.6	\$7.8	\$10.4	\$15.2	\$20.0	\$60.4
Anjeso	June 2020	\$0.3	\$0.1	\$0.1	\$0.2	\$0.2		\$0.9
ZYNRELEF	July 2021	\$2.1						\$2.1

\*Source: Net product revenue & launch dates based on SEC filings.



## **ZYNRELEF is Gaining Rapid Formulary Access**

#### ZYNRELEF formulary approvals: 126 as of October 31, 2021

Over 91% P&T Committee approval rate in hospitals

Formulary Approval Status	Estimated % of Approvals		
Unrestricted Usage	55%		
Restricted (Primarily for Indicated Procedures)	45%		


- Over 150 additional P&T Committees are scheduled to review ZYNRELEF before the end of 2021
- Formulary approval → Medical Executive approval → CPOE → Pharmacy Orders → Patient


**CPOE**: computerized physician order entry



#### **ZYNRELEF** is Gaining Significant Traction Despite COVID-19

- 160 unique accounts ordered ZYNRELEF in Q3'21 (July '21 through Sept. '21)
  - Over 50% of accounts reordered ZYNRELEF in Q3'21 since their initial order





THEBAPELITICS

\* Source: Symphony Heath SNR

### **ZYNRELEF** Reimbursement Advantages

- Multiple Commercial and Medicaid payers covering >88 million lives have agreed to reimburse ZYNRELEF outside of the surgical DRG bundled payment in the ASC
  - Many of these covered lives are also reimbursed separately in the HOPD
- ZYNRELEF's lower price benefits all settings of care where local anesthetics are reimbursed as part of the surgical bundle payment
- CMS is still evaluating ZYNRELEF's pass-through application for separate payment
  - Until December 31, 2021, HOPDs and ASCs may bill for ZYNRELEF using Misc. C-code (C9399) with reimbursement at 95% of AWP.
- On November 2, 2021, CMS published the CY 2022 OPPS final rule and issued ZYNRELEF a C-code (C9088) for separate reimbursement in the ASC setting of care effective January 1, 2022

HOPD: Hospital Outpatient Department; ASC: Ambulatory Surgical Center; OPPS: Outpatient Prospective Payment System



## **ZYNRELEF** Priorities in Q4

- In-service accounts with recent formulary approvals
- Grow formulary access in targeted accounts
- Expand reimbursement advantages
- Prepare for expanded label indications



#### Targeting ~2.1M Procedures at Launch With \$450M Potential Value With Data Supporting Fast Uptake with Influential Specialties

Indicated Launch Targets									
Inguinal Hernia	<b>Bunion</b>	<b>TKA</b>							
617,100	481,300	1,051,000							
Closel	Closely-Related Procedures Without Promotion								
Other Hernia	Other Foot & Ankle	THA							
831,000	197,900	630,000							
Potential Combined Opportunity									
Total	Total	Total							
1,448,100	679,200	1,681,000							

- Orthopedic and general surgeons account for 10.6M procedures or 76% of the 14M high value market procedures
- Orthopedic and general surgeons account for 82% of Exparel market utilization
- Orthopedic surgeons are heavy influencers (P&T, new drugs, profitability) across all settings of care

Reference: DRG Claims Analysis, 2019 / May 2021 DRG USPI Market Research. High value market procedures selected on severity and duration of pain and opioid use validated thorough medical review Please see IMPORTANT SAFETY INFORMATION on pages 28 to 29 and full Prescribing Information, including Boxed Warning.



#### **ZYNRELEF** Competitive Position Across Settings of Care



## Hospital Inpatient 46% (6.5M procedures)

- Bundled in DRG
- 57% (3.7M) of inpatient procedures are done in 340B hospitals

¢	
<u>o</u> ar	
	<u>у</u>

## Hospital Outpatient 39% (5.4M procedures)

- 17% (0.9M) have Medicare reimbursement (3-year pass-through)
- 58% (3.1M) eligible for 340B discount
- Multiple SKUs lower average costs



#### Ambulatory Surgical Centers 15% (2.1M procedures)

- 18% (0.4M) eligible for Medicare reimbursement at ASP + 6%
- Multiple SKUs lower average costs

#### **OVERALL TOTAL**

~14M

**High Value** 

**Procedures**<sup>1</sup>

- ZYNRELEF has lower acquisition cost benefit versus Exparel
- ZYNRELEF will have HOPD reimbursement – 3-year pass-through
- ZYNRELEF will offer 340B pricing

## 54% of the opportunity lends itself to favorable reimbursement and access

76% of ~2.1M indicated launch procedures opportunity lends itself to favorable reimbursement and access

SKU: stock keeping unit. HOPD: hospital outpatient department. 1. Reference: 2019 DRG Claims Data: Procedures selected on severity and duration of pain and opioid use validated thorough medical review
Please see IMPORTANT SAFETY INFORMATION on pages 28 to 29 and full Prescribing Information, including Boxed Warning.



### ZYNRELEF Reimbursement & Pricing Creates Economic Benefits Across All Settings of Care

#### Medicare: ZYNRELEF Is Reimbursed Separately in HOPD and ASC

At Launch C9399	3-Year Pass-Through <sup>a</sup> Product-specific C-code		
Diagnosis-Related G	roup (DRG) Payment		
95% of AWP	<b>ASP + 6</b> % <sup>c</sup>		
95% of AWP	<b>ASP + 6</b> % <sup>c</sup>		
95% of AWP	<b>ASP + 6%</b> <sup>c,d</sup>		
	C9399 Diagnosis-Related G 95% of AWP 95% of AWP		

Heron has applied for a C-Code; CMS has indicated that it is still under review as of October 1, 2021

**Commercial Reimbursement Varies by Payer** 

 Multiple commercial & Medicaid payers covering >86 million lives have agreed to reimburse ZYNRELEF outside of the surgical DRG bundled payment in the ASC

- Coverage in both HOPD & ASC with many of covered lives

 Heron Connect helps customers navigate coding and reimbursement for ZYNRELEF

 Heron applied for a J-code, but the application was denied by CMS because it is used in surgery and not billed separately via a J-code; applications for Exparel have been denied 3 times by CMS

a. Heron will apply for transitional pass-through status for ZYNRELEF. Typically, pass-through status is for 3 years. b. Exparel (bupivacaine liposome injectable suspension) is a trademark of Pacira Pharmaceuticals, Inc. c. ZYNRELEF will be reimbursed at WAC + 3% until ASP is established. d. Effective January 1, 2019, ASCs are reimbursed at ASP + 6% for non-opioid postoperative pain management drugs, like ZYNRELEF, when administered during a surgical procedure.

HOPD: hospital outpatient department. AWP: average wholesale price. ASP: average selling price. ASC: ambulatory surgical center. WAC: wholesale acquisition cost.



### ZYNRELEF's Significant Economic Benefits Designed to Support Rapid Share Conversion and Broad Access

ASP + 6%

ZYNRELEF	WAC	340B	E	Exparel		340B				
400 mg/12 mg	\$267.50	\$203.57	266 mg (20 mL)		\$344.2	0 \$344.20				
200 mg/6 mg	\$135.50	\$103.12	133 mg (10 mL)		\$189.3	7 \$189.37				
ZYNRELEF Savings vs Exparel										
WAC \$/unit	WAC \$/unit WAG			B \$/unit	340B %					
~ \$77		22%		~\$141	41%					
~ \$54	~ \$54 28%		~\$86		46%					
Medicare NCR By Site of Care**										
		NCR 3	340B NCR HOP		PD ASC					
ZYNRELEF 400	\$71.	\$71.53			ASP +6%					
Exparel 266 mg	l	(\$344.	.20)	(\$344.20	))	ASP +6%				
<b>ZYNRELEF 200</b>	\$34.	50	\$3.45		ASP +6%					

(\$189.37)

#### **ZYNRELEF Economic Benefit vs. Exparel\***

- 340B accounts: >\$415 (400 mg to 266 mg) and >\$223 (200 mg to 133 mg)
- HOPD accounts: >\$354 (400 mg to 266 mg) and >\$192 (200 mg to 133 mg)
- Research has shown all customer segments were more sensitive to and favored acquisition cost over reimbursement\*\*
- Based on expected use of two vials at launch and 340b discounts, average price projected to be \$225

Does not include additional cost of bupivacaine to admix with Exparel to achieve efficacy

(\$189.37)

\*Comparing WAC acquisition cost to NCR reimbursement under Medicare/Exparel NCR assumes ASCs purchasing at WAC. †Medicare NCRs are shown based on estimated ASP reimbursement for ZYNRELEF and Exparel Q2'21 published ASP reimbursement. WAC: wholesale acquisition cost. NCR: net cost recovery. HOPD: hospital outpatient department. ASC: ambulatory surgical center. \*\*DRG Research Pricing Research 2018 and Mock P&T Research 2019



Please see **IMPORTANT SAFETY INFORMATION** on pages 28 to 29 and full Prescribing Information, including **Boxed Warning**.

Exparel 133 mg

#### 58% of Prioritized Target Accounts are Fast Moving

\$742M Total Hospital & ASC Branded Annual WAC\*

#### \$321M \$549M Green/Yellow Branded Annual WAC\* Branded WAC\*

	Accts	340B %	high value market Procedures	Indicated Launch Procedures	Branded Utilization		<b>0-3 Months</b> When will the account order post commercial availability of ZYNRELEF
Hospitals	705	53%	4.6M	1.2M	\$309M		4-8 Months
ASC	398	0%	414K	144K	\$13M		When will the account order post commercial availability of ZYNRELEF



\*Includes Exparel and Offirmev. **ASC:** ambulatory surgical center. **WAC:** wholesale acquisition cost. **References: 1.** Symphony Drug Market – 2020. **2.** LexisNexis Procedure Data August 2019 YTD.

## **Important Safety Information for Patients**

#### **Important Safety Information**

ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which:

- can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID.
- cannot be used during heart bypass surgery
- can increase the risk of gastrointestinal bleeding, ulcers, and tears.

ZYNRELEF should also not be used:

- if you are allergic to any components of ZYNRELEF, aspirin or other NSAIDs (such as ibuprofen or naproxen), or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines.
- as a paracervical block, during childbirth.

## **Important Safety Information for Patients (cont)**

The most common side effects of ZYNRELEF are constipation, vomiting, and headache.

The medicines in ZYNRELEF (a local anesthetic and an NSAID) can affect the nervous and cardiovascular system; may reduce the effects of some blood pressure medications; should be avoided if you have severe heart failure; may cause liver or kidney problems, a rare blood disorder or life-threatening skin or allergic reactions; may harm your unborn baby if received at 20 weeks of pregnancy or later; and may cause low red blood cells (anemia).

Tell your healthcare provider about all your medical conditions and about all the medicines you take including prescription or over-the-counter medicines, vitamins, or herbal supplements to discuss if ZYNRELEF is right for you.

Talk to your healthcare provider for medical advice about side effects. Report side effects to Heron at 1-844-437-6611 or to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The information provided here is not comprehensive.

#### Please see full Prescribing Information, including Boxed Warning

# Oncology Care Franchise

Q3'21 Review



## **CINV Franchise 2021 Outlook**

- Q3'21 CINV Franchise net product sales were **\$21.2 million** (6% increase over prior year)
- Solid performance despite headwinds remaining in the CINV market
  - Reduction in the clinic anti-emetic market was due to COVID-related decreases in cancer screening and patient visits
  - OCM and value-based contracting reimbursement continues to drive generics market share
  - Continued aggressive competition from IV Akynzeo and generic fosaprepitant
- Sales for CINVANTI and SUSTOL are poised for clinic growth in 2022
  - Generic fosaprepitant ASP reimbursement decreased to **\$36.45** in Q4'21 (decrease of 27% vs. prior QTR)
  - Virtually all HEC and majority of MEC regimens utilize 5HT3 + NK-1, thus the backlog of patients coming into treatment creates opportunities for both products
- CINV Franchise net product sales guidance: Q4'21 expected in \$20M to \$22M range



OCM: Oncology Care Model

#### Heron's CINV Portfolio Net Sales Have Stabilized in Markets Dominated by Generics during 2021, Poised for Growth in 2022

- After declining after the launch of generic Emend IV in September 2019, CINVANTI sales have stabilized
- SUSTOL sales rebounding in 2021 following the Refresh Program




**CINV** portfolio net sales by guarter

THERAPEUTICS

Note: SUSTOL sales from Q4 2016- Q4 2017 of \$32.05M not shown in graph

## SUSTOL Removed Discounting in Q4'2019 with Refresh Program Completed in 2020 & Return to Growth in 2021



THERAPEUTICS

## Heron's Commercial Strategy

#### Establish Heron as a leading company in Acute Care

- ZYNRELEF is off to a fast start and growing rapidly
- Growth will accelerate with ZYNRELEF's label expansion
- Expand Acute Care footprint with HTX-019 for PONV in 2022

#### **Return Growth and Maximize Profitability of Oncology Care**

- Net sales stabilized in 2021 and poised for moderate growth in 2022
- Reduce COGS through larger scale manufacturing in 2022
- Aligned resources to support the strategy



## **Financial Summary**

Heron had cash, cash equivalents and short-term investments of \$202.8 million as of September 30, 2021. We expect net cash used for operating activities of \$45 million to \$48 million in the fourth quarter of 2021, and we anticipate that our net cash usage will continue to moderate lower in 2022.

Summary Statement of Operations and Net Cash Used in Operations (In thousands, except per share amounts)	Three Months Ended September 30, 2021	Nine Months Ended September 30, 2021
Net product sales	\$ 23,230	\$ 65,691
Operating expenses <sup>1</sup>	74,938	229,982
Other income (expense), net	(700)	(1,746)
Net loss <sup>1</sup>	\$ (52,408)	\$ (166,037)
Net loss per share <sup>2</sup>	\$ (0.51)	\$ (1.71)
Net cash used in operations	\$ (53,166)	\$ (158,096)
Condensed Balance Sheet Data (In thousands)	September 30, 2021	
Cash, cash equivalents and short-term investments	\$ 202,820	
Accounts receivable, net	\$ 43,086	
Total assets	\$ 352,388	
Total stockholders' equity	\$ 118,843	

Common shares outstanding as of September 30, 2021 totaled 101.9 million.

<sup>1</sup> Includes \$11.2 million and \$34.0 million of non-cash, stock-based compensation expense for the three and nine months ended September 30, 2021, respectively.

<sup>2</sup> Based on 101.9 million and 97.3 million weighted-average common shares outstanding for the three and nine months ended September 30, 2021, respectively.



35